Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jean-Christophe Tellier | CEO & Executive Director | 4.1M | -- | 1959 |
| Ms. Sandrine Dufour CFA | Executive VP, CFO & Chief Corporate Development | -- | -- | 1966 |
| Dr. Kirsten Lund-Jurgensen Ph.D. | Executive Vice President of Supply & Technology Solutions | -- | -- | 1960 |
| Ms. Denelle J. Waynick Johnson J.D. | Executive VP & General Counsel | -- | -- | 1967 |
| Mr. Jean-Luc Fleurial | Executive VP & Chief Human Resources Officer | -- | -- | 1965 |
| Mr. Emmanuel Caeymaex | Executive VP & Chief Commercial Officer | -- | -- | 1969 |
| Ms. Fiona du Monceau | Executive Vice President of Patient Evidence | 164k | -- | 1978 |
| Ms. Caroline Vancoillie | Chief Accounting Officer, Head of Group Finance & CFO of Patient Value Functions | -- | -- | -- |
| Mr. Alistair Henry | Executive VP & Chief Scientific Officer | -- | -- | 1967 |
| Ms. Antje Witte | Head of Investor Relations | -- | -- | -- |
UCB SA
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 9,000
Description
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Corporate Governance
Upcoming Events
February 27, 2025 at 6:00 AM UTC
UCB SA Earnings Date
Recent Events
April 26, 2024 at 12:00 AM UTC
Ex-Dividend Date